Pall to Invest $114 Million to Expand its Global Production Capacity
The company plans to expand its global production capacity across six existing manufacturing facilities in Europe and the United States, as well as a new manufacturing facility in the US.
Pall Corporation announced on Jan. 7, 2021 that it is investing $114 million to expand its global production capacity across six existing manufacturing facilities in Europe and the United States, as well as a new manufacturing facility in the US.
The investment will expand the production and distribution of single-use technology, media, and breathing filters at the company’s manufacturing facilities in Medemblik, Netherlands; Hoegaarden, Belgium; Bad Kreuznach, Germany; Ilfracombe, UK; Newquay, UK; Fajardo, Puerto Rico; and Pensacola, FL, Pall said in a company press release. The new US facility will focus on single-use technology to support the development and production of vaccines and therapeutics, including the COVID-19 vaccine.
The new venture will also produce more than 1100 jobs globally from now until the end of 2021.
"Pall’s global capacity expansion will ensure our critical products are manufactured and delivered to our customers so people around the world have access to lifesaving vaccines and genes therapies," said Joseph Repp, president, Pall Life Sciences, in the press release.
Source: Pall
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
